MBTPS1 and COVID-19: Consequently, and owing to the life-threatening hyperinflammatory syndrome induced by SARS-COV2 infections [31], three clinical trials were launched to use S1P-S1RPs agonists (Fingolimod, Opaganib) against COVID-19 (Clinicaltrials.gov identifiers: NCT04280588, NCT04467840, NCT04414618).